Cargando…
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452070/ https://www.ncbi.nlm.nih.gov/pubmed/30052728 http://dx.doi.org/10.1093/annonc/mdx076 |
| _version_ | 1783240311911219200 |
|---|---|
| author | Kang, S. P. Gergich, K. Lubiniecki, G. M. de Alwis, D. P. Chen, C. Tice, M. A. B. Rubin, E. H. |
| author_facet | Kang, S. P. Gergich, K. Lubiniecki, G. M. de Alwis, D. P. Chen, C. Tice, M. A. B. Rubin, E. H. |
| author_sort | Kang, S. P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5452070 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54520702018-03-12 Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic Kang, S. P. Gergich, K. Lubiniecki, G. M. de Alwis, D. P. Chen, C. Tice, M. A. B. Rubin, E. H. Ann Oncol Industry Corner: Perspectives and Controversies Oxford University Press 2017-06 2017-04-04 /pmc/articles/PMC5452070/ /pubmed/30052728 http://dx.doi.org/10.1093/annonc/mdx076 Text en © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Industry Corner: Perspectives and Controversies Kang, S. P. Gergich, K. Lubiniecki, G. M. de Alwis, D. P. Chen, C. Tice, M. A. B. Rubin, E. H. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic |
| title | Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic |
| title_full | Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic |
| title_fullStr | Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic |
| title_full_unstemmed | Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic |
| title_short | Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic |
| title_sort | pembrolizumab keynote-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic |
| topic | Industry Corner: Perspectives and Controversies |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452070/ https://www.ncbi.nlm.nih.gov/pubmed/30052728 http://dx.doi.org/10.1093/annonc/mdx076 |
| work_keys_str_mv | AT kangsp pembrolizumabkeynote001anadaptivestudyleadingtoacceleratedapprovalfortwoindicationsandacompaniondiagnostic AT gergichk pembrolizumabkeynote001anadaptivestudyleadingtoacceleratedapprovalfortwoindicationsandacompaniondiagnostic AT lubinieckigm pembrolizumabkeynote001anadaptivestudyleadingtoacceleratedapprovalfortwoindicationsandacompaniondiagnostic AT dealwisdp pembrolizumabkeynote001anadaptivestudyleadingtoacceleratedapprovalfortwoindicationsandacompaniondiagnostic AT chenc pembrolizumabkeynote001anadaptivestudyleadingtoacceleratedapprovalfortwoindicationsandacompaniondiagnostic AT ticemab pembrolizumabkeynote001anadaptivestudyleadingtoacceleratedapprovalfortwoindicationsandacompaniondiagnostic AT rubineh pembrolizumabkeynote001anadaptivestudyleadingtoacceleratedapprovalfortwoindicationsandacompaniondiagnostic |